Cerus vs Treace Medical Concepts
Cerus reported revenue of $234 million in fiscal 2025, about the same as Treace Medical Concepts' $213 million in fiscal 2025. Cerus' revenue grew 16.1% in its latest year, and Treace Medical Concepts' grew 1.6%. Cerus had an operating margin of -3.7%, against -25.5% at Treace Medical Concepts. Free cash flow was $1 million at Cerus and −$29 million at Treace Medical Concepts.
Side by side
| Cerus | Treace Medical Concepts | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $234M | $213M |
| Revenue growth | 16.1% | 1.6% |
| Revenue growth a year, last 5 years | 15.4% | 29.9% |
| Gross margin | — | 79.8% |
| Operating margin | −3.7% | −25.5% |
| Net margin | −6.7% | −27.7% |
| Free cash flow | $1M | −$29M |
| Free cash flow margin | 0.5% | −13.9% |
| Return on capital | — | −45.8% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.3% | 1.9% |
| Last close | $1.90 | $4.35 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $3.1 million | bought $1.4 million, sold $0 |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CerusTreace Medical Concepts
Operating margin
Percent of revenue
CerusTreace Medical Concepts
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CerusTreace Medical Concepts
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cerus and Treace Medical Concepts pages.